Pediatric Cancer – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 4 PAGES: 50

More Info
									                 Pediatric Cancer – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1933IDB
                                                                                              Publication Date: April 2012




Pediatric Cancer – Pipeline Review, H1 2012                                                   GMDHC1933IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Pediatric Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
Pediatric Cancer Overview ................................................................................................................................................................. 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for Pediatric Cancer ................................................................................................................. 8
Pediatric Cancer Therapeutics under Development by Companies ................................................................................................. 10
Pediatric Cancer Therapeutics under Investigation by Universities/Institutes................................................................................... 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Early Clinical Stage Products ........................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Pre-Clinical Stage Products.............................................................................................................................................................. 14
    Comparative Analysis .................................................................................................................................................................. 14
Pediatric Cancer Therapeutics – Products under Development by Companies ............................................................................... 15
Pediatric Cancer Therapeutics – Products under Investigation by Universities/Institutes ................................................................ 16
Companies Involved in Pediatric Cancer Therapeutics Development .............................................................................................. 17
    Novartis AG ................................................................................................................................................................................. 17
    Innogene Kalbiotech Pte Ltd........................................................................................................................................................ 18
    PharmaMar, S.A. ......................................................................................................................................................................... 19
Pediatric Cancer – Therapeutics Assessment .................................................................................................................................. 20
    Assessment by Monotherapy Products ....................................................................................................................................... 20
    Assessment by Combination Products ........................................................................................................................................ 21
    Assessment by Route of Administration ...................................................................................................................................... 22
    Assessment by Molecule Type .................................................................................................................................................... 24
Drug Profiles..................................................................................................................................................................................... 26
    LBH589 - Drug Profile ................................................................................................................................................................. 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    Racotumomab - Drug Profile ....................................................................................................................................................... 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    Vinorelbine + Cyclophosphamide - Drug Profile .......................................................................................................................... 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30
    Yondelis - Drug Profile ................................................................................................................................................................. 31
         Product Description................................................................................................................................................................. 31



Pediatric Cancer – Pipeline Review, H1 2012                                                                                                        GMDHC1933IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Pediatric Cancer – Pipeline Review, H1 2012




         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 31
    Carboplatin + Etoposide + Autologous bone marrow reinfusion - Drug Profile ............................................................................ 33
         Product Description................................................................................................................................................................. 33
         Mechanism of Action ............................................................................................................................................................... 33
         R&D Progress ......................................................................................................................................................................... 33
    COPP + ABV - Drug Profile ......................................................................................................................................................... 34
         Product Description................................................................................................................................................................. 34
         Mechanism of Action ............................................................................................................................................................... 35
         R&D Progress ......................................................................................................................................................................... 36
    Therapeutic Autologous Dendritic Cells + Indinavir Sulfate + Stem Cell Transplantation - Drug Profile ...................................... 37
         Product Description................................................................................................................................................................. 37
         Mechanism of Action ............................................................................................................................................................... 37
         R&D Progress ......................................................................................................................................................................... 38
    SCH 717454 - Drug Profile .......................................................................................................................................................... 39
         Product Description................................................................................................................................................................. 39
         Mechanism of Action ............................................................................................................................................................... 39
         R&D Progress ......................................................................................................................................................................... 39
    MLN8237 - Drug Profile ............................................................................................................................................................... 40
         Product Description................................................................................................................................................................. 40
         Mechanism of Action ............................................................................................................................................................... 40
         R&D Progress .............................................................................................................................................................
								
To top